GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » Cash Flow from Financing

Usana Health Sciences (Usana Health Sciences) Cash Flow from Financing : $-14.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Usana Health Sciences paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $0.8 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It spent $0.1 Mil on other financial activities. In all, Usana Health Sciences earned $0.7 Mil on financial activities for the three months ended in Dec. 2023.


Usana Health Sciences Cash Flow from Financing Historical Data

The historical data trend for Usana Health Sciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences Cash Flow from Financing Chart

Usana Health Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -152.05 -59.44 -181.41 -30.09 -14.24

Usana Health Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -3.20 -0.06 -11.64 0.66

Usana Health Sciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Usana Health Sciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Usana Health Sciences's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Usana Health Sciences  (NYSE:USNA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Usana Health Sciences's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Usana Health Sciences's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Usana Health Sciences's net issuance of debt for the three months ended in Dec. 2023 was $0.8 Mil. Usana Health Sciences received $0.8 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Usana Health Sciences's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. Usana Health Sciences paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Usana Health Sciences's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. Usana Health Sciences received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Usana Health Sciences's other financing for the three months ended in Dec. 2023 was $-0.1 Mil. Usana Health Sciences spent $0.1 Mil on other financial activities.


Usana Health Sciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Usana Health Sciences (Usana Health Sciences) Business Description

Traded in Other Exchanges
Address
3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
Executives
John Turman Fleming director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Gilbert A Fuller officer: CFO and Executive V.P. 55 WANDERWOOD WAY, SANDY UT 84092
Frederic J Winssinger director 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018
David Mulham Mulham officer: Chief Field Development Office 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Paul A. Jones officer: CFO 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Xia Ding director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Daniel A. Macuga officer: Chief Communications Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Jim Brown officer: Chief Production Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Brent Neidig officer: CO & Man. Dir. of China 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
J Scott Nixon director 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102
Kevin Guest officer: E.V.P. of Marketing 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Joshua Foukas officer: Chief Legal Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
G Doug Iiekking officer: VP of Finance C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot officer: Chief Information Officer 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott officer: Chief Scientific Officer 400 55 WATER STREET, VANCOUVER A1 V6B1A1